Osiris Therapeutics Announces Third Quarter 2012 Financial Results Conference Call

  Osiris Therapeutics Announces Third Quarter 2012 Financial Results
  Conference Call

Business Wire

COLUMBIA, Md. -- October 29, 2012

Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that it will report
its financial results for the third quarter ended September 30, 2012, on
Monday, November 5, 2012. C. Randal Mills, Ph.D., President and Chief
Executive Officer, and Philip R. Jacoby, Jr., Chief Financial Officer, will
provide a company update and discuss results via a webcast and conference call
on Monday, November 5, 2012 at 9:00 a.m. ET.

To access the webcast, visit the Investor Relations section of the company's
website at http://investor.osiris.com/events.cfm. Alternatively, callers may
participate in the conference call by dialing (877) 303-6133 (U.S.
participants) or (970) 315-0493 (international participants).

An archive of the webcast will be available approximately two hours after the
completion of the call through November 12, 2012. To access the archived
webcast, visit the Investor Relations section of the company's website at

About Osiris Therapeutics

Osiris Therapeutics, Inc. is the leading stem cell company, having developed
the world’s first approved stem cell drug, Prochymal®. The company is focused
on developing and marketing products to treat medical conditions in
inflammatory, cardiovascular, orthopedic and wound healing markets. In
Biosurgery, Osiris currently markets Grafix® for burns and chronic wounds, and
Ovation® for orthopedic applications. Osiris is a fully integrated company
with capabilities in research, development, manufacturing and distribution of
stem cell products. Osiris has developed an extensive intellectual property
portfolio to protect the company's technology, including 48 U.S. and 144
foreign patents.

Osiris, Prochymal, Grafix and Ovation are registered trademarks of Osiris
Therapeutics, Inc. More information can be found on the company's website,
www.Osiris.com. (OSIR-G)

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking
statements include statements about our expectations, beliefs, plans,
objectives, intentions, assumptions and other statements that are not
historical facts. Words or phrases such as "anticipate," "believe,"
"continue," "ongoing," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project" or similar words or phrases, or the
negatives of those words or phrases, may identify forward-looking statements,
but the absence of these words does not necessarily mean that a statement is
not forward-looking. Examples of forward-looking statements may include,
without limitation, statements regarding any of the following: our product
development efforts; our clinical trials and anticipated regulatory
requirements, and our ability to successfully navigate these requirements; the
success of our product candidates in development; status of the regulatory
process for our biologic drug candidates; implementation of our corporate
strategy; our financial performance; our product research and development
activities and projected expenditures, including our anticipated timeline and
clinical strategy for mesenchymal stem cells and biologic drug candidates and
marketed Biosurgery products (including Prochymal®, Chondrogen^TM, Grafix® and
Ovation®); our cash needs; patents, trademarks and other proprietary rights;
the safety and ability of our products and potential products to treat
disease; our ability to supply a sufficient amount of our marketed products or
product candidates and, if approved or otherwise commercially available,
products to meet demand; our costs to comply with governmental regulations;
our plans for sales and marketing; our plans regarding facilities; types of
regulatory frameworks we expect will be applicable to our products and
potential products; and results of our scientific research. Forward-looking
statements are subject to known and unknown risks and uncertainties and are
based on potentially inaccurate assumptions that could cause actual results to
differ materially from those expected or implied by the forward-looking
statements. Our actual results could differ materially from those anticipated
in forward-looking statements for many reasons, including the factors
described in the section entitled "Risk Factors" in our Annual Report on Form
10-K and other Periodic Reports filed on Form 10-Q, with the United States
Securities and Exchange Commission. Accordingly, you should not unduly rely on
these forward-looking statements. We undertake no obligation to publicly
revise any forward-looking statement to reflect circumstances or events after
the date of this press release or to reflect the occurrence of unanticipated


Osiris Therapeutics, Inc.
Erica Elchin, (443) 545-1834
Press spacebar to pause and continue. Press esc to stop.